Eurobio Scientific Société anonyme (ENXTPA:ALERS) agreed to acquire Genome Diagnostics B.V. from Ampersand Capital Partners and others for €135 million on August 17, 2022. The acquisition will be financed entirely in cash, with the Group's cash and partially through a bank loan for a total of 90 million euros. In 2021, GenDx generated €17 million in revenue, for €6.9 million in EBITDA. Completion of this operation is subject to the finalization of the bank financing contract. Finalization of a €90 million bank loan confirmed on On September 30, 2022, by the Group's bank syndicate with LCL, BNP, Credit. Agricole Ile de France, BRED and CIC.Floris Pierik, Renaud Bonnet, Maarten De Boorder of Jones Day acted as legal advisor to Eurobio Scientific Société anonyme (ENXTPA:ALERS). William Blair & Company, L.L.C. acted as financial advisor to Genome Diagnostics B.V. Herke van Hulst, Job van der Pol, Jim Margry, Cars-Jan van Gool, Coen Barneveld Binkhuysen, Joanne Zaaijer and Axel van der Staak of Osborne Clarke LLP acted as legal advisor to Genome Diagnostics B.V. Elena Coluccelli, Philippe de Montreynaud and Dimitrios Iroidis of Rothschild & Co SCA (ENXTPA:ROTH) acted as financial advisor to Eurobio Scientific Société anonyme. Justin Hamers, Martijn Koedijk and Thomas Fischer of Deloitte provided Financial due diligence.

Eurobio Scientific Société anonyme (ENXTPA:ALERS) completed the acquisition of Genome Diagnostics B.V. from Ampersand Capital Partners and others on October 3, 2022.